KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, launched of KBI PUREplatform, a microbial cell line development (CLD) platform designed to create efficiencies in a microbial expression system for biopharmaceutical production. The platform addresses industry challenges such as low titers, poor product quality, and capacity constraints, and aims to help customers significantly improve processes.

Engineered for commercial use, the platform features KBI’s PUREcoli high-producing E. coli cell line, paired with PUREplasmids and PUREmedia available in 8, 24, 48, and 96 screening packages – with future strains and screening packages under development. A robust, efficient platform, predictive development, and scalable high throughput workflows quickly feed upstream process development and late-stage manufacturing. The protein expression is individually tailored to each customer’s requirements.

“With the introduction of the KBI PUREplatform, we’re poised to extend the boundaries of expression system and process synergy, underscoring KBI’s commitment to innovation and customer-centric solutions across all business segments,” said Sigma Mostafa, KBI Biopharma’s chief scientific officer. “We always strive to stay a step ahead with significant production advancements. With this platform, we’re redefining the microbial expression landscape and raising the floor of efficiencies to create new market opportunities for scalable expression systems.”

The advanced system and modified strain outperform common K-12 or B strain E. coli by growing 50% faster, reducing production time by nearly half a day per batch. According to the company, PUREcoli stands out for its safety and efficiency, with 100 fewer virulence or immunogenicity related genes, eliminating the need for antibiotics in plasmid maintenance.

“The results our development team is seeing with PUREplatform are paving the way for our partners to realize microbial drug substance at a fraction of the scales previously needed, and we hope to see this translate into more efficient cost of goods for at-scale manufacturing,” said J.D. Mowery, CEO of KBI Biopharma.